Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS

Neurology

Volumn 65, Issue 11, 2005, Pages 1834-1836

  Ferrante, K L ^a   Shefner, J ^b   Zhang, H ^a   Betensky, R ^a   O'Brien, M ^a   Yu, H ^a   Fantasia, M ^a   Taft, J ^b   Beal, M F ^c   Traynor, B ^a   Newhall, K ^a   Donofrio, P ^d   Caress, J ^d   Ashburn, C ^d   Freiberg, B ^d   O'Neill, C ^d   Paladenech, C ^d   Walker, T ^d   Pestronk, A ^e   Abrams, B ^e   Florence, J ^e   Renna, R ^e   Schierbecker, J ^e   Malkus, B ^e   Cudkowicz, M ^a   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; PLACEBO; UBIDECARENONE; DRUG DERIVATIVE; NEUROPROTECTIVE AGENT; SCAVENGER; UBIQUINONE;

ABDOMINAL PAIN; ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; ELECTRON TRANSPORT; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INFECTION; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL RESPIRATION; MULTICENTER STUDY; NAUSEA; PERIPHERAL EDEMA; PRIORITY JOURNAL; RASH; URINARY TRACT INFECTION; BLOOD; CENTRAL NERVOUS SYSTEM; DOSE RESPONSE; DRUG EFFECT; ENERGY METABOLISM; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; MITOCHONDRION; NERVE CELL; NERVE DEGENERATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

AMYOTROPHIC LATERAL SCLEROSIS; CENTRAL NERVOUS SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; ENERGY METABOLISM; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MITOCHONDRIA; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; UBIQUINONE;

EID: 33645068499     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000187070.35365.d7     Document Type: Article

References (9)

1. Beal M. Mitochondria and the pathogenesis of ALS. Brain 2000;123:1291-1292.
2. Beal M, Matthews R. Coenzyme Q10 in the central nervous system and its potential usefulness in the treatment of neurodegenerative diseases. Mol Aspects Med 1997;18:s169-s179.
3. Huntington Study Group (Kieburtz K). A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001;57:397-404.
4. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-1550.
5. Ibrahim WH, Bhagavan HN, Chopra RK, Chow CK. Dietary coenzyme Q10 and vitamin E alter the status of these compounds in rat tissues and mitochondria. J Nutr 2000;130:2343-2348.
6. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci. 1994;124(suppl):96-107.
7. Mosca F, Fattorini D, Bompadre S, Littarru GP. Assay of CoQ10 in plasma by a single dilution step. Anal Biochem 2002;305:49-54.
8. Cudkowicz ME, Shefner JM, Brown RH, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003;61:456-464.
9. Shults CW, Beal MF, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol 2004;188:491-494.